tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Staar Surgical Concludes Go-Shop Period with Alcon

Story Highlights
  • STAAR Surgical’s go-shop period ended with no competing acquisition offers.
  • The outcome supports STAAR’s board’s decision to merge with Alcon, countering Broadwood’s claims.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Staar Surgical Concludes Go-Shop Period with Alcon

TipRanks Cyber Monday Sale

The latest announcement is out from Staar Surgical ( (STAA) ).

On December 8, 2025, STAAR Surgical Company announced the expiration of its go-shop period, which ended on December 6, 2025, as part of its amended merger agreement with Alcon Inc. During this period, STAAR actively solicited acquisition proposals from 21 third parties but received no competing offers, validating the effectiveness of its board’s sale process. The outcome discredits allegations from Broadwood Partners, L.P. about ignored acquisition interest, confirming Alcon as the best buyer for STAAR.

The most recent analyst rating on (STAA) stock is a Hold with a $25.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.

Spark’s Take on STAA Stock

According to Spark, TipRanks’ AI Analyst, STAA is a Neutral.

Staar Surgical’s overall stock score reflects significant financial and operational challenges, with negative profitability and liquidity issues being the most impactful factors. Technical analysis indicates bearish momentum, and valuation metrics are unfavorable. The proposed merger with Alcon provides a potential positive catalyst, but legal uncertainties cloud the outlook.

To see Spark’s full report on STAA stock, click here.

More about Staar Surgical

STAAR Surgical Company is a global leader in implantable phakic intraocular lenses (IOLs), specifically the EVO family of Implantable Collamer Lenses (ICLs) for vision correction. The company, headquartered in Lake Forest, California, has been dedicated to ophthalmic surgery since 1982 and has sold over 3 million ICLs in more than 75 countries. STAAR operates research, development, manufacturing, and packaging facilities in California and Switzerland.

Average Trading Volume: 929,440

Technical Sentiment Signal: Sell

Current Market Cap: $1.26B

Find detailed analytics on STAA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1